Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

This phase 3 SUNMO trial evaluated the combination of mosunetuzumab and polatuzumab vedotin (Mosun-Pola) versus rituxima...

Continue ReadingMosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.